(MDCO) The Medicines Company Earnings Well Above on Lower Costs

The Medicines Company (MDCO) reported a third-quarter profit of 40 cents per share Incorporatedluding the impact of stock-based compensation expense. Third quarter profit was well above the Zacks Consensus Estimate of 24 cents and the year-ago loss of 6 cents. Performance was boosted by higher revenues and lower operating expenses. Revenues, although up 6.9% at $105.7 million, fell short of the Zacks Consensus Estimate of $110 million. The Quarter in Detail Angiomax continued to see strong demand during the quarter. Angiomax sales in the US increased 9% to $100.2 million with Angiomax box sales increasing 14% from the year-ago period. EU sales increased 38% to $4 million mainly due to strong growth in countries like Italy, Switzerland, Spain, France, Scandinavia, and the United Kingdom. RoW sales, however, declined 42% to